Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Indofarma Tbk. (INAF) vs Suparma Tbk. (SPMA) Price & Performance

Indofarma Tbk.Trade
Suparma Tbk.Trade

Price performance (Past 24H)

Key statistics

Indofarma Tbk. vs Suparma Tbk. — how do they compare? Indofarma Tbk. trades at Rp126 (market cap 390.51B), while Suparma Tbk. trades at Rp172 (market cap 927.49B, 1.3M 24h volume). The key difference: Suparma Tbk. is far larger — about 2.4× Indofarma Tbk.'s market cap. Which is the better fit depends on your goals.

INAFSPMA
Market Cap
390.51B927.49B
Volume
1.3M
Lot
13.04K
Turnover
222.79M
Average Price
170.84
Value
222.79M
Indicative Equilibrium Price
172
Indicative Equilibrium Volume
102

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

INAF
View details
SPMA
View details

About Indofarma Tbk.

PT Indonesia Farma Tbk, known as PT Indofarma (Persero) Tbk (the Company) was established based on Deed No. 1 dated January 2, 1996 as amended by Deed No. 134 dated January 26, 1996 both of Notary Sutjipto, SH. PT. Indofarma, Tbk began as medicine factory well known as "Pabrik Obat Manggarai". Then take over by Japan's Government from Nederland's Government on 1942. On 1950 the Indonesian Government acquisited the factory by Department of Health and functioned as center of pharmacy production for its department. On 1979 the name changed to be Department of Health Center of Pharmacy Production as non Profit institution as main assignment to produced medicine for public service. Then the Company changed the name as PT. Indonesia Farma Tbk, known as PT Indofarma (Persero) Tbk.

Read more on INAF

About Suparma Tbk.

PT Suparma Tbk (Entity) was established under the Domestic Capital Investment Law No. 6 of 1968 as amended by Law No. 12 of 1970 based on the Notarial Deed No. 29 of Tjahjadi Hartanto, S.H., on August 25, 1976. The Entity's name, PT Supar Inpama was changed to PT Suparma based in the Notarial Deed No. 5 dated December 7, 1978 of the same notary.

Read more on SPMA